Patrick J. Doyle

Chief Business Officer at Synthorx, Inc.

Patrick J. Doyle

Patrick J. Doyle

Chief Business Officer at Synthorx, Inc.

Overview
Career Highlights

KineMed, Inc.
Stelexis Therapeutics LLC
Ipsen Bioinnovation Ltd.

RelSci Relationships

379

Number of Boards

1

Relationships
RelSci Relationships are individuals Patrick J. Doyle likely has professional access to. A relationship does not necessarily indicate a personal connection.

Co-Founder at KineMed, Inc.

Relationship likelihood: Strong

Co-Founder at KineMed, Inc.

Relationship likelihood: Strong

Secretary at Emiliem, Inc.

Relationship likelihood: Strong

Partner at Latterell Venture Partners

Relationship likelihood: Strong

Chairman & Chief Executive Officer at Talfinium Investments, Inc.

Relationship likelihood: Strong

Chief Scientific Advisor at Protagenic Therapeutics, Inc.

Relationship likelihood: Strong

Executive Director & Principal at The Sage Group

Relationship likelihood: Strong

Research Scientist at Max Planck Society

Relationship likelihood: Strong

Former Partner-Life Sciences Practice at Ernst & Young LLP

Relationship likelihood: Strong

Former Chief Operating Officer at Syntaxin Ltd.

Relationship likelihood: Strong

Paths to Patrick J. Doyle
Potential Connections via
Relationship Science
You
Patrick J. Doyle
Chief Business Officer at Synthorx, Inc.
Education

The University of Sunderland is a truly life-changing university. They have been providing higher education in the city since 1901, and they are proud to be an innovative, accessible and inspirational university.

University of Geneva is a public research university located in Geneva, Switzerland.

Career History
Chief Executive Officer
Prior

Syntaxin is a biopharmaceutical company that engineers and develops bacterial-based protein therapeutics for the treatment of neurological, inflammatory and endocrine diseases. The biopharmaceutical company's proprietary technology platform enables the engineering of bacterial proteins by domain substitution, to produce novel cell-specific biotherapeutics that inhibit cell secretion. These products can have therapeutic effects in a wide range of indications.

Chief Development Officer
Prior

CymaBay Therapeutics, Inc. is a clinical stage biopharmaceutical company, focused on developing and providing access to therapies for patients with liver and other chronic diseases with high unmet medical need. Its products include MBX-8025 and Arhalofenate, MBX-8025 aims to treat lipid and liver diseases while Arhalofenate intends to reduce gout flares and serum uric acid. The company was founded on October 5, 1988 and is headquartered in Newark, CA.

Scientific Coordinator
1995 - 2000

Novo Nordisk, Inc. operates diabetes care company. It offers biopharmaceuticals, chronic weight management, human growth hormone therapy and hemophilla management services. The firm also provides rare bleeding disorders, growth hormone related disorders, and women's health. The company was founded in 1982 and is headquartered in Plainsboro, NJ.

Boards & Committees
President & Director
2014 - 2016

KineMed, Inc. develops and commercializes biomarker platform technology. It provides dynamic proteomics platform, a functionally interpretable systems biology platform. The company was founded by David M. Fineman and Marc K. Hellerstein in February 2001 and is headquartered in Emeryville, CA.

Transactions
Details Hidden

KineMed, Inc. raised money in a private placement transaction

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Patrick J. Doyle. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Patrick J. Doyle's profile does not indicate a business or promotional relationship of any kind between RelSci and Patrick J. Doyle.